Purple Biotech (PPBT) announced the initiation of a Phase 2 clinical study evaluating NT219 in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck, R/M SCCHN. NT219 is a novel small molecule designed to target two key oncogenic pathways: IRS1/2 and STAT3. NT219 induces the degradation of IRS1/2 and inhibits the phosphorylation of STAT3, thereby, blocking their respective signaling pathways. The Phase 2 study will evaluate NT219 in combination with either pembrolizumab or cetuximab, both of which are standard-of-care treatments in R/M SCCHN patients. Additionally, the study aims to evaluate potential biomarkers identified in a previous clinical study of NT219.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PPBT:
- Purple Biotech’s Clinical Advancements and Strategic Collaborations Highlight Promising Future
- Purple Biotech Reports Q1 2025 Financial Results and Advances Clinical Programs
- Purple Biotech reports Q1 EPS 17c
- Purple Biotech Appoints New CFO Amid Strategic Growth
- Purple Biotech appoints Shai Lankry as CFO